JUNS — Jupiter Neurosciences Cashflow Statement
0.000.00%
- $20.53m
- $16.91m
Annual cashflow statement for Jupiter Neurosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS/A | PROSPECTUS/A | PROSPECTUS/A | PROSPECTUS/A | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -1.65 | -4.2 | -4.96 | -4.78 | -2.44 |
Non-Cash Items | 0.373 | 1.68 | 2.16 | 1.95 | 1.09 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 1.03 | 0.781 | 1.55 | 2.35 | -2.57 |
Change in Accounts Receivable | |||||
Change in Other Assets | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Cash from Operating Activities | -0.255 | -1.74 | -1.25 | -0.481 | -3.91 |
Financing Cash Flow Items | — | 0.5 | — | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 0.462 | 1.86 | 0.982 | 0.445 | 7.65 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0.207 | 0.123 | -0.266 | -0.036 | 3.74 |